Lead Product(s) : Brazikumab
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Termination
AstraZeneca Regains Global Rights to Brazikumab From Allergan
Details : AstraZeneca and Allergan have terminated their previous license agreement and all rights to brazikumab have therefore now returned to AstraZeneca.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 11, 2020
Lead Product(s) : Brazikumab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : Brazikumab
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Divestment
AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep
Details : AstraZeneca will acquire brazikumab, in Phase 2b/3 development for Crohn's Disease and in Phase 2 development for ulcerative colitis, including global development and commercial rights.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 27, 2020
Lead Product(s) : Brazikumab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Divestment
Lead Product(s) : HIL-214
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
HilleVax’s Norovirus Vaccine Fails Phase 2 Trial, Stock Falls 80%
Details : HIL-214, an investigational IM vaccine for norovirus-related gastroenteritis, did not meet its primary endpoint in the NEST-IN1 trial. The company will stop its development in infants aged 5 months.
Brand Name : HIL-214
Molecule Type : Vaccine
Upfront Cash : Not Applicable
July 08, 2024
Lead Product(s) : HIL-214
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Guselkumab
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Tremfya (guselkumab) is a selective IL-23 p19 inhibitor antibody, which is being evaluated for the treatment of moderately to severely active ulcerative colitis.
Brand Name : Tremfya
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 23, 2023
Lead Product(s) : Guselkumab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MH002
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MH002 is currently the most advanced rationally-designed consortium therapy, which is investigated for the treatment of mild-to-moderate Ulcerative Colitis.
Brand Name : MH002
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
September 19, 2023
Lead Product(s) : MH002
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Brazikumab
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : AbbVie Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Update on Brazikumab Development Programme
Details : MEDI2070 (brazikumab) discontinuation of the inflammatory bowel disease development programme, an anti-IL-23 monoclonal antibody, being investigated for the treatment of Crohn’s disease (CD) and ulcerative colitis (UC)
Brand Name : MEDI2070
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 01, 2023
Lead Product(s) : Brazikumab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : AbbVie Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Clonidine
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
Details : Validive® (clonidine hydrochloride) is a novel mucobuccal tablet (MBT) formulation of clonidine. The mucobuccal tablet provides for prolonged local delivery of clonidine to the regions of oral mucosal radiation damage in oropharyngeal cancer (OPC) patie...
Brand Name : Validive
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 27, 2022
Lead Product(s) : Clonidine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Guselkumab
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : New data show proportions of patients treated with TREMFYA (guselkumab) who achieved clinical-biomarker response ranged from 47.5-66.7 percent across dose groups in the Phase 2 GALAXI 1 study.
Brand Name : Tremfya
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 24, 2022
Lead Product(s) : Guselkumab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable